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ABSTRACT
Human immunodeficiency virus (HIV) is transmitted predominantly through sexual intercourse. Research suggests 
that the vaginal epithelium acts as a barrier to HIV transmission, but this epithelium can be disrupted, leading to 
HIV infection and other sexually transmitted infections. Topical microbicides are considered an effective strategy for 
HIV prevention, and several candidate drugs are currently in clinical trials. However, significant concerns about drug 
adherence, efficacy, and safety must be addressed in order to develop a safe and effective microbicide. This paper will 
provide an overview of the field and strategies to overcome some of the obstacles facing microbicide development, 
and briefly discuss a research project that focused on one aspect of preclinical microbicide safety testing.
INTRODUCTION
A
ccording to the 2007 report by the Joint United 
Nations Program on HIV/AIDS (UNAIDS), 
33,200,000 people are living with HIV, and 
2,500,000 were infected in 2007 (Barton-
Knott 2007). The predominant mode of transmission 
is sexual, and women now account for the majority of 
HIV-infected individuals (Cutler and Justman 2008). The 
multilayered epithelium of the female genital mucosa is 
thought to act as a barrier to virus transmission, and dis-
ruption of this epithelium due to microabrasions, pres-
ence of other infections, or use of chemicals, including 
nonoxynol-9, a commonly used spermicide, increases the 
risk of HIV infection (Cutler and Justman 2008). Effective 
prevention strategies include condoms and male circum-
cision, which reduce the risk of males acquiring HIV and 
thus could affect the global epidemic (Katz and Wright 
2008). Although condoms are an effective barrier against 
HIV, women often do not have a choice about whether 
a condom is used during intercourse. In addition, many 
women who trade sex for food or money may not be 
using condoms and possibly have daily repeated expo-
sure to HIV-infected men.
Researchers are developing vaginal microbicides as a 
strategy to prevent HIV transmission. Theoretically, 
these microbicides, which would be composed of anti-
viral agents formulated as a gel, foam, or cream, could 
be applied vaginally (or rectally) to prevent the trans-
mission of HIV and possibly other sexually transmitted 
infections. Additionally, these products might protect 
the epithelium from microabrasions and other disrup-
tions of the epithelial barrier associated with sex. A list 
of candidate microbicides and their status in clinical tri-
als is presented in tables 1 and 2. With the possibility of a 
safe and effective HIV vaccine still years from becoming 
a reality, many researchers have turned to topical micro-
bicides as a more attainable focus for HIV prevention.
Although microbicides appear to be a promising and 
exciting strategy for HIV prevention, the field has also 
been mired in controversies over adequate preclinical 
testing of drug efficacy and safety. 
DRUG SAFETY 
The significance of inadequate drug-safety evalua-
tions before embarking on clinical trials was first illus-
trated by the failed phase 3 trials of Nonoxynol-9 (N-9). 
Although N-9, a surfactant used for years as a contracep-
tive, initially appeared safe in preclinical safety experi-
ments, the phase 3 study of the drug demonstrated 
that N-9 actually increased the relative risk of HIV infec-
tion among women who used the product frequently 
(Moscicki 2008). 
These results spurred researchers to study the mecha-
nisms by which N-9 might enhance HIV acquisition and 
to develop models that better predict microbicide safety. 
Initial results demonstrated that N-9 triggered the release 
of inflammatory cytokines and chemokines, which could 
recruit HIV target cells and augment HIV transcription 
through activation (Fichorova et al. 2001). In subsequent 
studies conducted by the Herold laboratory, repeated 
application of N-9 in mice not only induced an inflamma-
tory response, but also caused disruption in the epithelial 
barrier with down-regulation of tight junction proteins 
(Wilson et al. 2009). Disruption resulted in an increased 
susceptibility to HSV-2, and suggested that the disrup-
tion might also increase susceptibility to HIV (Wilson 
2009). These findings, in hindsight, would have predicted 
the outcome of the failed N-9 trials, and they illustrate 
the importance of optimizing preclinical models to bet-
ter evaluate the safety of candidate microbicides before 
implementing large-scale clinical trials.
14  EJBM, Copyright © 2011
Development of Preclinical Biomarkers Predictive of Safety of Vaginal Microbicides for the Prevention of HIV
4Scientific Review
Unfortunately, other phase 2/3 clinical trials of candi-
date microbicides have also been prematurely halted 
by the Data Safety Monitoring Board due to concerns 
over safety or futility. For example, a double-blind pla-
cebo-controlled randomized trial of 6% cellulose sulfate 
(CS) gel (Ushercell) was prematurely stopped because 
of higher rates of HIV acquisition in the treatment arm. 
In the final data analysis of 1,398 patients, there were 
41 new HIV infections, 25 (out of 706 patients) in the 
cellulose sulfate group and 16 (out of 692 patients) in 
the placebo group, resulting in a hazard ratio of infec-
tion for cellulose sulfate of 1.61 (95% confidence inter-
val [CI], 0.86 to 3.01; P=0.13) (Van Damme et al. 2008). 
Extensive preclinical and phase 1 clinical studies, which 
included measurements of inflammatory cytokines, had 
indicated that CS gel was safe. Thus, the disappointing 
results of the clinical-efficacy trial highlight again the 
need for expanding and improving models to evaluate 
microbicide efficacy and safety. Similarly, a phase 2/3 trial 
PC-515 microbicide gel (Carraguard) was carried out to 
completion without any safety concerns; however, the 
drug failed to demonstrate efficacy (Skoler-Karpoff et al. 
2008). A recently completed trial comparing 0.5% PRO 
2000 gel, buffer gel, placebo gel, and condoms alone 
has also demonstrated no significant reduction in HIV 
risk (Roehr 2009). Recent follow-up studies suggest that 
the lack of efficacy with PRO 2000 and Carraguard may 
reflect a loss in antiviral activity in the setting of semen 
and a decrease in drug bioavailability following coitus. 
Specifically, while genital-tract secretions collected by 
lavage had significant anti-HIV activity following appli-
cation of a single dose of PRO 2000 gel, there was little 
or no activity in lavage fluid obtained after sex, and the 
concentration of drug recovered was markedly reduced 
(Keller et al. 2010). These findings highlight the need 
for pharmacokinetic and pharmacodynamic studies that 
include postcoital sampling.
THE POTENTIAL ROLE OF SEMEN IN HIV INFECTION
With multiple drugs passing current preclinical safety 
measures but having no positive effect in clinical trials, 
the potential for success with the microbicide strategy 
has been hotly debated. Modification and optimization 
of preclinical and early clinical testing may be needed to 
identify candidate drugs and formulations that are more 
likely to prove both safe and effective. Most preclinical 
trials have tested the efficacy of microbicides by study-
ing the ability of the drugs to prevent viral infection in 
cell or tissue models with virions diluted in media or buf-
fer (Patel et al. 2007). However, while these studies may 
demonstrate a high level of efficacy, they are not rep-
resentative of viral infection in vivo, where the virus is 
present in semen and interacts with cervicovaginal secre-
tions (Patel et al. 2007). A new technique that mimics 
physiological conditions may better assess microbicide 
safety before the drug enters clinical trials.
In an effort to evaluate microbicide efficacy in a more 
physiological model, the Herold laboratory tested the 
efficacy of two phase 2b/3 microbicides, PRO 2000 and 
cellulose sulfate, in the presence of biological fluids 
(Patel et al. 2007). Semen and cervicovaginal secretions 
Table 2: Candidate microbicides in completed clinical trials 
Current Clinical Trials
Candidate Mechanism Current Status – Phase 
Tenofovir gel
Nucleotide reverse transcriptase inhibitor; HIV-
specific
Ongoing—Phase IIB,
rings in early development
VivaGel
Anionic polymer, blocks viral entry by 
interfering with receptor-ligand interactions; 
active against HIV & other STI
Phase I completed,
data analysis ongoing
Dapivirine
Non-nucleoside reverse transcriptase inhibitor; 
HIV-specific
Ongoing—Phase I, 
gel and intravaginal ring
UC-781
Nonnucleoside reverse transcriptase inhibitor, 
prevents HIV infection in CD4+ T cells
Phase I completed,
expanded PK study planned
PC-815 Carraguard plus MIV-150, a nonnucleoside RTI Planned—Phase I
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were collected from healthy individuals with low risk for 
sexually transmitted diseases (Patel et al. 2007). Human 
cervical epithelial cells were incubated with the micro-
bicides diluted in cervicovaginal lavage (CVL) fluid and 
then challenged with serial dilutions of HIV or herpes 
simplex virus type 2 (HSV-2) diluted in phosphate buff-
ered saline (PBS), seminal plasma, or a buffer matched 
for the pH and total protein concentration of seminal 
plasma (Patel et al. 2007). Both PRO 2000 and cellulose 
sulfate lost substantial and significant antiviral activ-
ity under those conditions. In contrast, tenofovir, a 
reverse transcriptase inhibitor formulated as a vaginal 
gel and currently being evaluated in several phase 2/3 
clinical trials, retained its anti-HIV activity in the pres-
ence of CVL and seminal plasma (Patel et al. 2007). 
These in vitro results were supported by in vivo exper-
iments in a murine model. All mice treated with PRO 
2000 gel were protected from HSV-2 infection when 
the virus was presented in PBS; however, only 55% of 
the mice survived when the virus was introduced in 
seminal plasma (Patel et al. 2007). Subsequent frac-
tionation studies identified two proteins in the seminal 
plasma that contributed to the observed interference 
with anti-HSV activity of the microbicide: fibronectin 
and lactoferrin (Patel et al. 2007). Mechanistic studies 
demonstrated that these seminal plasma proteins com-
peted with the microbicides for binding sites on the 
HSV viral envelope glycoproteins, thus blocking the 
ability of the drugs to prevent HSV binding and entry.
Interest in the role of seminal plasma proteins in HIV 
infection has been further sparked by a recent study 
demonstrating that a seminal protein called prostatic 
acidic phosphatase (PAP) forms amyloid fibrils that pro-
mote HIV attachment to target cells and significantly 
increases HIV infection (Münch et al. 2007). Given that a 
majority of HIV infections arise from exposure to semen 
from HIV-positive men (Royce et al. 1997), understand-
ing the significance of semen in HIV transmission and its 
role in the mechanism of infection is crucial.
THE EFFECT OF SEMINAL FLUID IN AN IN VITRO 
DUAL-CHAMBER MODEL OF HIV INFECTION AND 
MICROBICIDE EFFICACY AND SAFETY
During the summer of 2008, the Herold laboratory 
began a project to better assess drug safety, focusing 
on the development of an in vitro model to evaluate 
the impact microbicides have on the epithelial barrier. 
Table 2: Candidate microbicides in completed clinical trials 
Completed Clinical Trials
Candidate Mechanism Results 
Nonoxynol-9 Detergent, disrupts viral envelope
Trial stopped, 
no efficacy*
C31G Detergent, disrupts viral envelope
Trial stopped, 
no efficacy*
Carraguard
Anionic polymer, blocks viral entry by interfering with 
receptor-ligand interactions
Trial completed, 
no efficacy
Cellulose sulfate
Anionic polymer, blocks viral entry by interfering with 
receptor-ligand interactions
Trial stopped, 
no efficacy*
BufferGel Acid-buffering gel to maintain acidic pH in vagina
Trial completed, 
no efficacy
PRO 2000
Anionic polymer, blocks viral entry by interfering with 
receptor-ligand interactions; active against HIV & other STI
Trials completed,
no efficacy
 
*Trend toward increased HIV
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To simulate what might happen in vivo, the laboratory 
developed a dual-chamber culture model system using 
Transwell inserts. Human epithelial cells (HEC1A cell 
line), representing the female genital mucosa, were 
cultured in the upper chamber of the Transwell inserts 
and T cells were cultured in the lower compartment. 
The upper chamber represents the environment that 
the genital epithelial mucosa may be exposed to dur-
ing sexual intercourse (i.e., semen, microbicides, and HIV 
virions); the lower chamber represents the submucosal 
layer and lamina propria, where T cells, targets for HIV, 
are found. The HEC1A cells, a human endometrial cell 
line, were chosen because they polarize well and form 
tight junctions that are relatively impervious to HIV. 
Thus, the only way a virus crosses this barrier is through 
a disruption in the epithelium. Epithelial integrity was 
measured by transepithelial resistance (TER), and HIV 
infection in the basolateral supernatants was quantified 
by an enzyme-linked immunosorbent assay (ELISA) of 
p24, the HIV capsid protein.
First, the cytotoxic effects of seminal fluid were investi-
gated in the model. It was found that exposure of HEC1A 
cells to 50% or 100% seminal fluid for greater than six 
hours was toxic; thus, all subsequent experiments were 
conducted with 25% seminal plasma and the exposure 
time was limited to six hours. 
Next, whether seminal fluid had any deleterious impact 
on the epithelial barrier was examined by monitoring 
changes in TER and the ability of HIV to migrate across 
the barrier and infect T cells cultured in the basal com-
partment. The HEC1A cells were exposed to pooled 
human seminal fluid or a control buffer for a single 
two-hour exposure or daily two-hour exposures for four 
consecutive days and then inoculated apically with HIV. 
Results demonstrated that both single and repeated 
exposures to seminal fluid did not significantly decrease 
TER nor enhance the ability of HIV to permeate the epi-
thelial barrier, as indicated by no increase in p24. 
Next, the impact of microbicides on the epithelial barrier 
was evaluated with virus introduced in the presence or 
absence of seminal plasma. Both a single eighteen-hour 
exposure and daily two-hour exposures to N-9 resulted 
in a marked and rapid drop in TER. Consistent with this 
was a significant increase in p24 levels, indicating that 
the destruction of the epithelial barrier allowed for unin-
hibited increased HIV migration and subsequent infec-
tion of T cells cultured in the lower compartment. These 
results were not surprising, given the cytotoxic and sur-
factant nature of N-9. However, what was unanticipated 
was that exposure to CS at concentrations as low as 100 
mcg/ml triggered approximately a 50% drop in the TER. 
Similar results were observed following either a single 
eighteen-hour exposure or repeated daily two-hour 
exposures. The drop in TER was associated again with 
an increase in HIV permeability, resulting in productive 
infection of T cells cultured in the lower compartment. 
The same experiments with N-9 and CS were subsequently 
conducted in the presence of seminal fluid to exam-
ine whether it would change the drugs’ effects on TER 
and p24 levels. It was hypothesized that seminal fluid—
which is a complex mixture of proteins, sugars, ions, and 
enzymes—could either augment or prevent the disrupt-
ing effects of the microbicides. HEC1A cells were treated 
with CS or N-9 and seminal fluid for four two-hour treat-
ments over four days, and then were exposed to HIV 
after the fourth treatment. For both N-9 and CS, TER still 
decreased rapidly, and there was a corresponding increase 
in p24 levels. These findings suggest that the effects of 
CS and N-9 on epithelial integrity and HIV transmission 
could not be averted by the presence of seminal fluid.
Under these experimental conditions, seminal fluid itself 
had little impact on the ability of HIV to cross the epi-
thelium and infect T cells cultured in the basolateral 
compartment. Moreover, the toxic effects of N-9 and CS 
persisted when the epithelium was exposed to drugs and 
seminal fluid. Currently, these in vitro models are being 
expanded to better understand mechanisms by which 
HIV overcomes the epithelial barrier to infect immune 
cells in vivo and are being developed as biomarkers to 
evaluate microbicide safety.  
CONCLUSION
The growing HIV epidemic demands rapid development 
of a prevention strategy. Vaginal microbicides have the 
potential to provide a safe and inexpensive method to 
reduce viral transmission. Recent disappointing results 
in multiple clinical drug trials have raised concerns 
about adequate microbicide preclinical safety testing. To 
address these issues, researchers are translating the clini-
cal results back to the bench with the goal of develop-
ing preclinical and early clinical assays that might prove 
more predictive of safety and efficacy for future micro-
bicides in development. Validation of these models will 
require testing of additional microbicides and correlat-
ing results with clinical trial outcomes.
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